Iovance Biotherapeutics Inc. (0JDK)
LSE
13.19
-1.09 (-7.67%)
Real-time Data
07:00 AM
Day's Range
12.9214.26
52 wk Range
1.7615.30
Financial Statements - 0JDK - Iovance Biotherapeutics Inc.
Revenue
308.00M▲ 79.7%
Net Income
123.30M▲ 289.0%Net Margin 40.0%
EBITDA
264.60M▲ 84.0%
Free Cash Flow
-733.60M▼ 613.4%
Income Statement
| Period Ending | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|
| Sales | 308M | 171.40M | 268.40M | 273.80M |
| Cost of Goods | 105.40M | 107M | 127.80M | 145M |
| Gross Profit | 202.60M | 64.40M | 140.60M | 128.80M |
 Operating Expense | - | - | - | - |
| Operating Income | 162.80M | 39.30M | 110.80M | 103.40M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | 157.70M | 37.80M | 109.20M | 102.90M |
| Income Tax | 34.40M | 6.10M | -2.20M | 23.50M |
| Net Income | 123.30M | 31.70M | 111.40M | 79.40M |
| EPS Basic | 0.55 | 0.14 | 0.48 | 0.34 |
| EPS Diluted | 0.55 | 0.14 | 0.48 | 0.34 |
| Basic Shares Outstanding | 223.30M | 229.60M | 233.60M | 235.10M |
| Diluted Shares Outstanding | 223.30M | 229.60M | 233.60M | 235.10M |
| Ebit | - | - | - | - |
| Ebitda | 264.60M | 143.80M | 234M | 243.60M |
| Net Income Continuous Operations | 123.30M | 31.70M | 111.40M | 79.40M |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
